Selected research
Market Structure
Global Neutropenia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neutropenia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neutropenia Drugs include Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC and Richter Gedeon Nyrt., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Neutropenia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neutropenia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neutropenia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neutropenia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Neutropenia Drugs Segment by Company
Apotex Inc.
Biogenomics Limited
Cellerant Therapeutics, Inc.
Coherus BioSciences, Inc.
Dr. Reddy’s Laboratories Limited
Ligand Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Prolong Pharmaceuticals, LLC
Richter Gedeon Nyrt.
Sandoz International GmbH
Neutropenia Drugs Segment by Type
Capsule
Injection
Neutropenia Drugs Segment by Application
Hospital
Clinic
Neutropenia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neutropenia Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neutropenia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neutropenia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neutropenia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Injection
Applications
- Hospital
- Clinic
Companies covered
- Apotex Inc.
- Biogenomics Limited
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Dr. Reddy’s Laboratories Limited
- Ligand Pharmaceuticals, Inc.
- NAL Pharmaceuticals Ltd.
- Prolong Pharmaceuticals, LLC
- Richter Gedeon Nyrt.
- Sandoz International GmbH
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neutropenia Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neutropenia Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Neutropenia Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Neutropenia Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Neutropenia Drugs Market Dynamics
- 2.1 Neutropenia Drugs Industry Trends
- 2.2 Neutropenia Drugs Industry Drivers
- 2.3 Neutropenia Drugs Industry Opportunities and Challenges
- 2.4 Neutropenia Drugs Industry Restraints
3 Neutropenia Drugs Market by Manufacturers
- 3.1 Global Neutropenia Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Neutropenia Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Neutropenia Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Neutropenia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Neutropenia Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neutropenia Drugs Manufacturers, Product Type & Application
- 3.7 Global Neutropenia Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neutropenia Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neutropenia Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Neutropenia Drugs Tier 1, Tier 2, and Tier 3
4 Neutropenia Drugs Market by Type
- 4.1 Neutropenia Drugs Type Introduction
- 4.1.1 Capsule
- 4.1.2 Injection
- 4.2 Global Neutropenia Drugs Sales by Type
- 4.2.1 Global Neutropenia Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neutropenia Drugs Sales by Type (2021-2032)
- 4.2.3 Global Neutropenia Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Neutropenia Drugs Revenue by Type
- 4.3.1 Global Neutropenia Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Neutropenia Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Neutropenia Drugs Revenue Market Share by Type (2021-2032)
5 Neutropenia Drugs Market by Application
- 5.1 Neutropenia Drugs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global Neutropenia Drugs Sales by Application
- 5.2.1 Global Neutropenia Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neutropenia Drugs Sales by Application (2021-2032)
- 5.2.3 Global Neutropenia Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Neutropenia Drugs Revenue by Application
- 5.3.1 Global Neutropenia Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Neutropenia Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Neutropenia Drugs Revenue Market Share by Application (2021-2032)
6 Global Neutropenia Drugs Sales by Region
- 6.1 Global Neutropenia Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neutropenia Drugs Sales by Region (2021-2032)
- 6.2.1 Global Neutropenia Drugs Sales by Region (2021-2026)
- 6.2.2 Global Neutropenia Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neutropenia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Neutropenia Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neutropenia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Neutropenia Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neutropenia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Neutropenia Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neutropenia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Neutropenia Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Neutropenia Drugs Revenue by Region
- 7.1 Global Neutropenia Drugs Revenue by Region
- 7.1.1 Global Neutropenia Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Neutropenia Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Neutropenia Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Neutropenia Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Neutropenia Drugs Revenue (2021-2032)
- 7.2.2 North America Neutropenia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Neutropenia Drugs Revenue (2021-2032)
- 7.3.2 Europe Neutropenia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neutropenia Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Neutropenia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neutropenia Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Neutropenia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Apotex Inc.
- 8.1.1 Apotex Inc. Company Information
- 8.1.2 Apotex Inc. Business Overview
- 8.1.3 Apotex Inc. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Apotex Inc. Neutropenia Drugs Product Portfolio
- 8.1.5 Apotex Inc. Recent Developments
- 8.2 Biogenomics Limited
- 8.2.1 Biogenomics Limited Company Information
- 8.2.2 Biogenomics Limited Business Overview
- 8.2.3 Biogenomics Limited Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Biogenomics Limited Neutropenia Drugs Product Portfolio
- 8.2.5 Biogenomics Limited Recent Developments
- 8.3 Cellerant Therapeutics, Inc.
- 8.3.1 Cellerant Therapeutics, Inc. Company Information
- 8.3.2 Cellerant Therapeutics, Inc. Business Overview
- 8.3.3 Cellerant Therapeutics, Inc. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Cellerant Therapeutics, Inc. Neutropenia Drugs Product Portfolio
- 8.3.5 Cellerant Therapeutics, Inc. Recent Developments
- 8.4 Coherus BioSciences, Inc.
- 8.4.1 Coherus BioSciences, Inc. Company Information
- 8.4.2 Coherus BioSciences, Inc. Business Overview
- 8.4.3 Coherus BioSciences, Inc. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Coherus BioSciences, Inc. Neutropenia Drugs Product Portfolio
- 8.4.5 Coherus BioSciences, Inc. Recent Developments
- 8.5 Dr. Reddy’s Laboratories Limited
- 8.5.1 Dr. Reddy’s Laboratories Limited Company Information
- 8.5.2 Dr. Reddy’s Laboratories Limited Business Overview
- 8.5.3 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product Portfolio
- 8.5.5 Dr. Reddy’s Laboratories Limited Recent Developments
- 8.6 Ligand Pharmaceuticals, Inc.
- 8.6.1 Ligand Pharmaceuticals, Inc. Company Information
- 8.6.2 Ligand Pharmaceuticals, Inc. Business Overview
- 8.6.3 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product Portfolio
- 8.6.5 Ligand Pharmaceuticals, Inc. Recent Developments
- 8.7 NAL Pharmaceuticals Ltd.
- 8.7.1 NAL Pharmaceuticals Ltd. Company Information
- 8.7.2 NAL Pharmaceuticals Ltd. Business Overview
- 8.7.3 NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 NAL Pharmaceuticals Ltd. Neutropenia Drugs Product Portfolio
- 8.7.5 NAL Pharmaceuticals Ltd. Recent Developments
- 8.8 Prolong Pharmaceuticals, LLC
- 8.8.1 Prolong Pharmaceuticals, LLC Company Information
- 8.8.2 Prolong Pharmaceuticals, LLC Business Overview
- 8.8.3 Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Prolong Pharmaceuticals, LLC Neutropenia Drugs Product Portfolio
- 8.8.5 Prolong Pharmaceuticals, LLC Recent Developments
- 8.9 Richter Gedeon Nyrt.
- 8.9.1 Richter Gedeon Nyrt. Company Information
- 8.9.2 Richter Gedeon Nyrt. Business Overview
- 8.9.3 Richter Gedeon Nyrt. Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Richter Gedeon Nyrt. Neutropenia Drugs Product Portfolio
- 8.9.5 Richter Gedeon Nyrt. Recent Developments
- 8.10 Sandoz International GmbH
- 8.10.1 Sandoz International GmbH Company Information
- 8.10.2 Sandoz International GmbH Business Overview
- 8.10.3 Sandoz International GmbH Neutropenia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Sandoz International GmbH Neutropenia Drugs Product Portfolio
- 8.10.5 Sandoz International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Neutropenia Drugs Value Chain Analysis
- 9.1.1 Neutropenia Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neutropenia Drugs Production Mode & Process
- 9.2 Neutropenia Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neutropenia Drugs Distributors
- 9.2.3 Neutropenia Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst